Parathyroid Hormone Receptor Inverse Agonist (PTH-IA) Chemistry, Manufacturing, and Controls (CMC)

Solicitation
Person of Contact Jennifer Gnuschke (jennifer.gnuschke@nih.gov)
Proposal Due Date Wednesday, July 8, 2026 (Closed 5 days 23 hours ago)
NAICS Codes 541714, 541715
  • Research Category Research & Development Services & Subcontracts
  • Solicitation Number S26-XX55
  • NCI OA Contract Number 75N91019D00024 – NCI-FFRDC

Description

Request for Information (RFI) for INFORMATIONAL PURPOSES ONLY. Based on responses, a formal Request for Proposal (RFP) may be issued.

The Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center, currently operated by Leidos Biomedical Research, Inc. for the National Cancer Institute, is seeking information. The intent of this RFI is to obtain Rough Order of Magnitude (ROM) estimates for activities related to PTH-IA CMC; manufacture of formulated drug products for a phase I/II clinical trial for pediatric patients with Jansen Metaphyseal Chondrodysplasia (JMC).

Proposal Instructions

To obtain a copy of this RFI, please contact Jennifer Gnuschke at jennifer.gnuschke@nih.gov.

Specific questions regarding this RFI are due by 12:00 p.m. (ET) Wednesday, July 1, 2026.

RFI responses are due by 12:00 p.m. (ET) Wednesday, July 8, 2026.